GlassScriptPhysician profile
Jan Gillespie Wagner
NPI 1043293921
$1,789.23
in general payments reported to CMS, 2019-2025
12 companies · $451 in 2025
The $451 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $19.56 · 2021: $43.51 · 2022: $214 · 2023: $254 · 2024: $607 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.92 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $995.00 | 2022-2025 | |
| Pfizer INC. | $195.84 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $168.62 | 2024-2025 | Xeomin |
| Amgen INC. | $143.22 | 2019 | |
| Allergan, INC. | $83.64 | 2020-2022 | |
| Merz North America, INC. | $47.41 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $40.01 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.89 | 2022 | |
| Si-Bone, INC. | $26.09 | 2025 | |
| Depuy Synthes Sales INC. | $24.50 | 2024 | Orthovisc, Monovisc |
| Lilly USA, LLC | $19.37 | 2024 | Reyvow, Emgality |
| Indivior INC. | $17.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Gillespie Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.